title: Acute chemotherapy-induced cardiomyopathy treated with intracorporeal left ventricular assist device in an 8-year-old child.
abstract: Evolution of ventricular assist devices (VADs) leading to miniaturization has made intracorporeal implantation in children feasible. Ventricular assist device therapy for anthracycline-induced cardiomyopathy (CMP) in adults has been reported. We report the case of an 8-year-old child (body surface area 0.97 m) presenting with anthracycline-induced CMP being successfully treated with an intracorporeal left ventricular assist device (LVAD) as a bridge to candidacy/recovery. We present our institutional algorithm, which advises intracorporeal LVAD implantation for long-term ventricular assist, in children with a body surface area >0.6 m. Advantages are better mobilization and the possibility to discharge home, leading to enhanced quality of life.
authors.affiliation: Department of Congenital Cardiovascular Surgery, University Children's Hospital Zurich, Zurich, Switzerland. martin.schweiger@kispi.uzh.ch
authors.forename: Martin
authors.initials: M
authors.lastname: Schweiger
authors.forename: Hitendu
authors.initials: H
authors.lastname: Dave
authors.forename: Frithjof
authors.initials: F
authors.lastname: Lemme
authors.forename: Anna
authors.initials: A
authors.lastname: Cavigelli-Brunner
authors.forename: Olga
authors.initials: O
authors.lastname: Romanchenko
authors.forename: Bea
authors.initials: B
authors.lastname: Heineking
authors.forename: Michael
authors.initials: M
authors.lastname: Hofmann
authors.forename: Chrstoph
authors.initials: C
authors.lastname: Bürki
authors.forename: Brian
authors.initials: B
authors.lastname: Stiasny
authors.forename: Michael
authors.initials: M
authors.lastname: Hübler
mesh_terms: D000465:Algorithms; D018943:Anthracyclines / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D009202:Cardiomyopathies / Q000139:chemically induced* / Q000628:therapy*; D002648:Child; D004317:Doxorubicin / Q000009:adverse effects; D005260:Female; D005355:Fibrosis / Q000139:chemically induced; D006333:Heart Failure / Q000139:chemically induced; D006352:Heart Ventricles / Q000503:physiopathology; D006353:Heart-Assist Devices; D006801:Humans; D008727:Methotrexate / Q000009:adverse effects; D008904:Miniaturization; D009210:Myofibrils / Q000187:drug effects; D012519:Sarcoplasmic Reticulum / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D018943:Anthracyclines; D000970:Antineoplastic Agents; D004317:Doxorubicin; D008727:Methotrexate